ATE312097T1 - Polymorphe und andere kristalline formen von cis- ftc - Google Patents

Polymorphe und andere kristalline formen von cis- ftc

Info

Publication number
ATE312097T1
ATE312097T1 AT02748367T AT02748367T ATE312097T1 AT E312097 T1 ATE312097 T1 AT E312097T1 AT 02748367 T AT02748367 T AT 02748367T AT 02748367 T AT02748367 T AT 02748367T AT E312097 T1 ATE312097 T1 AT E312097T1
Authority
AT
Austria
Prior art keywords
ftc
cis
forms
manufacture
polymorphods
Prior art date
Application number
AT02748367T
Other languages
English (en)
Inventor
Kenneth R Phares
Devalina Law
Yuerong Hu
Original Assignee
Gilead Sciences Inc
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Abbott Lab filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ATE312097T1 publication Critical patent/ATE312097T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02748367T 2001-03-01 2002-03-01 Polymorphe und andere kristalline formen von cis- ftc ATE312097T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27256001P 2001-03-01 2001-03-01
US30960501P 2001-08-02 2001-08-02
PCT/US2002/006184 WO2002070518A1 (en) 2001-03-01 2002-03-01 Polymorphic and other crystalline forms of cis-ftc

Publications (1)

Publication Number Publication Date
ATE312097T1 true ATE312097T1 (de) 2005-12-15

Family

ID=26955597

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05076347T ATE383355T1 (de) 2001-03-01 2002-03-01 Polymorph und andere kristallinische formen von zusammen-ftc
AT02748367T ATE312097T1 (de) 2001-03-01 2002-03-01 Polymorphe und andere kristalline formen von cis- ftc

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05076347T ATE383355T1 (de) 2001-03-01 2002-03-01 Polymorph und andere kristallinische formen von zusammen-ftc

Country Status (14)

Country Link
US (3) US6723728B2 (de)
EP (3) EP1574512B1 (de)
JP (4) JP5105689B2 (de)
KR (4) KR101015510B1 (de)
CN (4) CN102911166B (de)
AT (2) ATE383355T1 (de)
AU (1) AU2002335489B2 (de)
CA (4) CA2788498C (de)
CY (2) CY1107983T1 (de)
DE (2) DE60224592T2 (de)
DK (2) DK1389207T3 (de)
ES (3) ES2253544T3 (de)
PT (2) PT1574512E (de)
WO (1) WO2002070518A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE383355T1 (de) * 2001-03-01 2008-01-15 Abbott Lab Polymorph und andere kristallinische formen von zusammen-ftc
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US20060014949A1 (en) * 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2009005338A2 (en) * 2007-07-05 2009-01-08 Ultimorphix Technologies B.V. Solid forms ult-i, ult-2 and ult-3 of emtricitabine
US20110288298A1 (en) 2008-11-12 2011-11-24 Lupin Limited novel polymorph of emtricitabine and a process for preparing of the same
US8710218B2 (en) 2009-07-15 2014-04-29 Lupin Limited Process for preparation of Efavirenz

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4476248A (en) 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
EP0141927B1 (de) 1983-08-18 1991-10-30 Beecham Group Plc Antivirale Guanin-Derivate
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
JPH03501253A (ja) 1987-09-22 1991-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア エイズ（ａｉｄｓ）治療を目的とするリポソームによるヌクレオシド類似物質
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5700937A (en) 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
EP0531452A4 (en) 1990-05-29 1993-06-09 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
US5674849A (en) 1990-10-24 1997-10-07 Allelix Biopharmaceuticals Inc. Anti-viral compositions
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US6228860B1 (en) * 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
IT1244501B (it) 1991-03-22 1994-07-15 Sigma Tau Ind Farmaceuti Derivati amminoacilici e oligopeptidici dell'allopurinolo dotati di attivita' immunostimolante e composizioni farmaceutiche che li contengono
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
CA2112803A1 (en) 1991-07-12 1993-01-21 Karl Y. Hostetler Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en) 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
JPH08510236A (ja) 1993-05-12 1996-10-29 カール ワイ． ホステトラー 局所使用のためのアシクロビル誘導体
GB9311709D0 (en) 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
US5808040A (en) 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
SE503154C2 (sv) * 1995-03-10 1996-04-01 Tony Wiseby Anordning vid sikte för pilbåge
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
DE19543707A1 (de) * 1995-11-23 1997-05-28 Inst Neue Mat Gemein Gmbh Verfahren zum Konservieren von Papier
GB9525606D0 (en) 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
WO1998023285A1 (en) 1996-11-29 1998-06-04 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis b
TW318283B (en) 1996-12-09 1997-10-21 United Microelectronics Corp Multi-level read only memory structure and manufacturing method thereof
EA005097B1 (ru) 1997-03-19 2004-10-28 Эмори Юниверсити Синтез 1,3-оксаселеноланнуклеозидов, обладающих активностью против вируса иммунодефицита человека и против вируса гепатита-b
CA2340214C (en) * 1998-08-12 2007-10-30 Triangle Pharmaceuticals, Inc. Method of manufacture of 1,3-oxathiolane nucleosides
IL142393A0 (en) 1998-10-09 2002-03-10 Altus Biologics Inc Non-homogeneous systems for the resolution of enantiomeric mixtures
ATE383355T1 (de) 2001-03-01 2008-01-15 Abbott Lab Polymorph und andere kristallinische formen von zusammen-ftc
CA2351049C (en) * 2001-06-18 2007-03-13 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers

Also Published As

Publication number Publication date
CA2867970A1 (en) 2002-09-12
CA2788498C (en) 2016-02-16
KR20080065317A (ko) 2008-07-11
JP2009197005A (ja) 2009-09-03
ATE383355T1 (de) 2008-01-15
US6723728B2 (en) 2004-04-20
US7544692B2 (en) 2009-06-09
AU2002335489B2 (en) 2008-06-05
CA2788498A1 (en) 2002-09-12
CN1503796B (zh) 2012-07-04
ES2253544T3 (es) 2006-06-01
WO2002070518A1 (en) 2002-09-12
CA2439831C (en) 2010-01-12
CA2690137A1 (en) 2002-09-12
DK1574512T3 (da) 2008-03-03
EP1903041A3 (de) 2008-04-23
US20030060645A1 (en) 2003-03-27
EP1389207A1 (de) 2004-02-18
CN102911165A (zh) 2013-02-06
CN102911165B (zh) 2016-08-17
CA2439831A1 (en) 2002-09-12
KR101150250B1 (ko) 2012-06-12
EP1903041A2 (de) 2008-03-26
EP1574512A1 (de) 2005-09-14
EP1903041B1 (de) 2015-02-18
CN102911166A (zh) 2013-02-06
KR20040002871A (ko) 2004-01-07
PT1903041E (pt) 2015-06-23
DE60207850D1 (de) 2006-01-12
DE60207850T2 (de) 2006-08-10
CN1503796A (zh) 2004-06-09
JP2004530660A (ja) 2004-10-07
JP5105689B2 (ja) 2012-12-26
ES2299950T3 (es) 2008-06-01
KR100927024B1 (ko) 2009-11-17
DE60224592D1 (de) 2008-02-21
CY1107983T1 (el) 2013-09-04
EP1574512B1 (de) 2008-01-09
DE60224592T2 (de) 2009-01-29
US20090306114A1 (en) 2009-12-10
US20050026934A1 (en) 2005-02-03
PT1574512E (pt) 2008-03-05
CN102911166B (zh) 2016-08-17
KR101015510B1 (ko) 2011-02-16
CN102942563A (zh) 2013-02-27
EP1389207B1 (de) 2005-12-07
US8637535B2 (en) 2014-01-28
KR20080065316A (ko) 2008-07-11
CY1107913T1 (el) 2013-09-04
ES2537007T3 (es) 2015-06-01
CA2690137C (en) 2012-11-13
JP2015028045A (ja) 2015-02-12
KR20100091265A (ko) 2010-08-18
DK1389207T3 (da) 2006-04-18
JP2013040192A (ja) 2013-02-28

Similar Documents

Publication Publication Date Title
CY1107913T1 (el) Πολυμορφικες και αλλες κρυσταλλικες μορφες cis-ftc
NO20031471L (no) Glykoformer av faktor VII
DK1140945T3 (da) Kondenserede 1,2,4-thiadiazinderivater, deres fremstilling og anvendelse
SE0102315D0 (sv) Compounds
PL366590A1 (en) Novel compounds as anti-inflammatorz, immunomodulatory and anti-proliferatory agents
NZ609146A (en) Modified 4’-nucleosides as antiviral agents
DE60330757D1 (de) Verwendung von pyridylamiden als angiogenesehemmer
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
WO2002034727A3 (en) Treatment of gastrointestinal stromal tumors
EA200400352A1 (ru) Органолептически приемлемые распадающиеся во рту композиции
WO2005004805A3 (en) Thermally stable crystalline epirubicin hydrochloride and method of making the same
EP1365782A4 (de) Magnesium-substituierte hydroxylapatite
PT1191025E (pt) Cristais de lansoprazol
PL1855677T3 (pl) 3,11B-Cis-dihydrotetrabenazyny do leczenia schizofrenii i innych psychoz
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
WO2004012687A3 (en) Crystalline and amorphous forms of beta-l-2'-deoxythymidine
DE602004031744D1 (de) Kristallisation von festen formen von clopidogreladditionssalzen
JP2003516941A5 (de)
WO2004046134A3 (en) Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
RU93045711A (ru) Нейролептические пергидро-1h-пиридо(1,2-a)пиразины, способ их получения, фармацевтическая композиция, способ лечения
MXPA03010205A (es) Derivados de acido oxalico.
RU98116525A (ru) Керамическая масса
DE60209795D1 (de) Zusammensetzungen enthaltend endgruppen-verkappte polyalkylenglykole
IL162983A (en) Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis
DE50309599D1 (de) Versatz zur herstellung eines feuerfesten keramischen formk rpers, daraus gebildeter formk rper und eine verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1389207

Country of ref document: EP